Information Provided By:
Fly News Breaks for December 13, 2019
Dec 13, 2019 | 05:31 EDT
Credit Suisse analyst Evan Seigerman downgraded Gilead Sciences to Underperform from Neutral with a price target of $63, down from $67. The company's setup for 2020 "remains challenging" with an "unclear" strategy from new management, Seigerman tells investors in a research note. The analyst remains concerned about Gilead's earnings and revenue growth.
News For GILD From the Last 2 Days
Feb 18, 2020 | 06:26 EST
Clinical trials being conducted in Wuhan to test Gilead's antiviral drug for the new coronavirus are going more slowly than hoped for as the drugmaker struggles to recruit qualified patients, The Wall Street Journal's Fanfan Wang reports. According to the report, the trials, which are aimed at testing more than 700 patients infected with the Wuhan coronavirus, have succeeded in recruiting fewer than 200 people after 10 days. A total of 168 patients with severe symptoms, and 17 patients with mild and moderate symptoms, were recruited at 11 medical institutes across Wuhan, Zhang Xinmin, an official from China's Ministry of Science and Technology, said at a Saturday press conference. Reference Link